(BME) BlackRock Health Sciences - Overview
Stock: Pharmaceuticals, Biotechnology, Medical Devices, Healthcare Services
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 8.30% |
| Yield on Cost 5y | 10.34% |
| Yield CAGR 5y | 6.55% |
| Payout Consistency | 92.7% |
| Payout Ratio | 162.8% |
| Risk 5d forecast | |
|---|---|
| Volatility | 11.5% |
| Relative Tail Risk | 1.72% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | 2.09 |
| Character TTM | |
|---|---|
| Beta | 0.465 |
| Beta Downside | 0.489 |
| Drawdowns 3y | |
|---|---|
| Max DD | 14.60% |
| CAGR/Max DD | 0.48 |
Description: BME BlackRock Health Sciences December 27, 2025
BlackRock Health Sciences Trust (NYSE:BME) is a closed-ended equity mutual fund managed by BlackRock Advisors, LLC that invests exclusively in U.S. publicly-traded companies engaged in health-related research, development, production, distribution, or delivery of medical, dental, optical, pharmaceutical, and biotechnology products and services. The fund also employs equity derivatives, primarily option-writing strategies, and measures its results against the Russell 3000 Healthcare Index. It was launched on March 31 2005 and is domiciled in the United States.
Key quantitative points (as of Q3 2024) include an expense ratio of 0.79%, total assets under management of roughly $1.2 billion, and a 5-year annualized total return of about 9.3%, which modestly outperformed the Russell 3000 Healthcare Index’s 8.7% over the same period. The fund’s performance is closely tied to sector drivers such as an aging U.S. population (projected to increase the over-65 demographic by 20 % by 2035), rising Medicare spending, and accelerated biotech innovation reflected in a 12 % year-over-year increase in U.S. biotech R&D expenditures.
For a deeper dive into the fund’s risk-adjusted metrics and comparative valuation, you might explore ValueRay’s analyst tools.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 42.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 3.59 > 1.0 |
| NWC/Revenue: -29.64% < 20% (prev -0.15%; Δ -29.48% < -1%) |
| CFO/TA 0.02 > 3% & CFO 8.21m > Net Income 42.9m |
| Net Debt (-39.4k) to EBITDA (23.5m): -0.00 < 3 |
| Current Ratio: 0.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (12.9m) vs 12m ago -7.31% < -2% |
| Gross Margin: 78.45% > 18% (prev 0.69%; Δ 7776 % > 0.5%) |
| Asset Turnover: 7.52% > 50% (prev 6.54%; Δ 0.98% > 0%) |
| Interest Coverage Ratio: 100.0k > 6 (EBITDA TTM 23.5m / Interest Expense TTM 87.0) |
Altman Z'' 10.00
| A: -0.02 (Total Current Assets 1.76m - Total Current Liabilities 14.3m) / Total Assets 528.6m |
| B: 0.27 (Retained Earnings 140.9m / Total Assets 528.6m) |
| C: 0.17 (EBIT TTM 92.8m / Avg Total Assets 562.4m) |
| D: 24.75 (Book Value of Equity 508.1m / Total Liabilities 20.5m) |
| Altman-Z'' Score: 27.81 = AAA |
What is the price of BME shares?
Over the past week, the price has changed by +0.55%, over one month by +2.06%, over three months by +11.10% and over the past year by +12.30%.
Is BME a buy, sell or hold?
What are the forecasts/targets for the BME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 47.5 | 12.7% |
BME Fundamental Data Overview February 05, 2026
P/B = 1.0671
Revenue TTM = 42.3m USD
EBIT TTM = 92.8m USD
EBITDA TTM = 23.5m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.41m USD (from shortTermDebt, last quarter)
Debt = 1.41m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -39.4k USD (from netDebt column, last quarter)
Enterprise Value = 543.5m USD (542.2m + Debt 1.41m - CCE 39.4k)
Interest Coverage Ratio = 1.07m (Ebit TTM 92.8m / Interest Expense TTM 87.0)
EV/FCF = 14.52x (Enterprise Value 543.5m / FCF TTM 37.4m)
FCF Yield = 6.88% (FCF TTM 37.4m / Enterprise Value 543.5m)
FCF Margin = 88.44% (FCF TTM 37.4m / Revenue TTM 42.3m)
Net Margin = 101.3% (Net Income TTM 42.9m / Revenue TTM 42.3m)
Gross Margin = 78.45% ((Revenue TTM 42.3m - Cost of Revenue TTM 9.12m) / Revenue TTM)
Gross Margin QoQ = 30.20% (prev 91.10%)
Tobins Q-Ratio = 1.03 (Enterprise Value 543.5m / Total Assets 528.6m)
Interest Expense / Debt = 0.01% (Interest Expense 87.0 / Debt 1.41m)
Taxrate = 21.0% (US default 21%)
NOPAT = 73.3m (EBIT 92.8m * (1 - 21.00%))
Current Ratio = 0.12 (Total Current Assets 1.76m / Total Current Liabilities 14.3m)
Debt / Equity = 0.00 (Debt 1.41m / totalStockholderEquity, last quarter 508.1m)
Debt / EBITDA = -0.00 (Net Debt -39.4k / EBITDA 23.5m)
Debt / FCF = -0.00 (Net Debt -39.4k / FCF TTM 37.4m)
Total Stockholder Equity = 627.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.62% (Net Income 42.9m / Total Assets 528.6m)
RoE = 6.83% (Net Income TTM 42.9m / Total Stockholder Equity 627.3m)
RoCE = 14.79% (EBIT 92.8m / Capital Employed (Equity 627.3m + L.T.Debt 0.0))
RoIC = 9.54% (NOPAT 73.3m / Invested Capital 768.7m)
WACC = 7.61% (E(542.2m)/V(543.6m) * Re(7.63%) + D(1.41m)/V(543.6m) * Rd(0.01%) * (1-Tc(0.21)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.73%
[DCF Debug] Terminal Value 80.37% ; FCFF base≈30.8m ; Y1≈32.7m ; Y5≈39.0m
Fair Price DCF = 56.84 (EV 734.6m - Net Debt -39.4k = Equity 734.6m / Shares 12.9m; r=7.61% [WACC]; 5y FCF grow 6.85% → 2.90% )
EPS Correlation: -58.29 | EPS CAGR: -23.93% | SUE: -0.09 | # QB: 0
Revenue Correlation: -17.99 | Revenue CAGR: -31.75% | SUE: N/A | # QB: 0